The two-sided 95 % confidence interval (CI) and odds ratio (OR) were calculated by estimation. A two-sided probability level of 5 % was considered significant. All statistical selleck products analyses were performed using the SAS software program for Windows (SAS Inc. Japan, Tokyo, Japan). Results Baseline demographics and clinical characteristics of participants according to eGFR level The baseline characteristics of the 2977 participants in the CKD-JAC study have been described previously [13]. Of them, the subjects check details in this study, i.e., those who were examined by echocardiography (UCG), consisted of 755 Japanese men

(63.7 %) and 430 Japanese women (36.3 %), 489 (41.3 %) and 918 (77.5 %) of whom had DM and dyslipidemia, respectively. Most of the subjects had hypertension (1051, 88.7 %) and were being treated with an antihypertensive agent Talazoparib datasheet (1095, 92.4 %), most of them (83.1 %) with ACE inhibitors (302, 25.5 %)/ARBs (901, 76.0 %), as shown in Table 1. Table 1 Baseline characteristics of study population by eGFR Variable All patients eGFR (ml/min/1.73 m2) P value Stage 3a Stage 3b Stage 4 Stage 5 ≥45 30 to <45 15 to <30 <15 N 1185 136 383 464 202   Age (years)

61.8 ± 11.1 56.7 ± 12.8 61.4 ± 11.4 62.9 ± 10.4 63.5 ± 9.8 <0.001 Sex [n (%)]           0.888  Male 755 (63.7) 86 (63.2) 246 (64.2) 299 (64.4) 124 (61.4)    Female 430 (36.3) 50 (36.8) 137 (35.8) 165 (35.6) 78 (38.6)   Medical history [n (%)]  Hypertension 1051 (88.7) 113 (83.1) 328 (85.6) 429 (92.5) 181 (89.6) 0.002  Diabetes 489 (41.3) 57 (41.9) 151 (39.4) 191 (41.2) 90 (44.6) 0.691  Dyslipidemia 918 (77.5) 106 (77.9) 292 (76.2) 363 (78.2) 157 (77.7) 0.916  Cardiovascular disease   MI 80 (6.8) 8 (5.9) 23 (6.0) 33 (7.1) 16 (7.9) 0.792   Angina 129 (10.9) 10 (7.4) 42 (11.0) 50 (10.8) 27 (13.4) 0.386   Congestive heart failure 67 (5.7) 4 (2.9) 21 (5.5) 27 (5.8) 15 (7.4) 0.375   ASO 43 (3.6) 3 (2.2) 9 (2.3) 21 (4.5) 10 (5.0) 0.199   Stroke 147 (12.4) 18 (13.2) 46 (12.0) 55 (11.9)

28 (13.9) 0.881 BMI (kg/m2) 23.6 ± 3.8 24.1 ± 3.3 23.7 ± 3.9 23.5 ± 3.8 23.4 ± 3.6 0.594 Blood pressure (mmHg)  Systolic 132.4 ± 18.1 130.8 ± 17.3 129.6 ± 17.5 133.3 ± 18.2 Bcl-w 136.9 ± 18.2 <0.001  Diastolic 75.9 ± 11.8 76.0 ± 10.9 75.1 ± 11.6 76.1 ± 11.9 76.7 ± 12.6 0.255 Pulse pressure (mmHg) 56.5 ± 13.9 54.8 ± 14.1 54.5 ± 13.5 57.2 ± 14.0 60.1 ± 13.6 <0.001 Creatinine (mg/dl) 2.18 ± 1.09 1.09 ± 0.17 1.43 ± 0.25 2.31 ± 0.53 4.05 ± 0.87 <0.001 eGFR (mL/min/1.73 m2) 28.61 ± 12.63 50.78 ± 5.26 37.12 ± 4.19 22.39 ± 4.29 11.85 ± 1.91 <0.001 Uric acid (mg/dl) 7.21 ± 1.51 6.48 ± 1.39 7.01 ± 1.32 7.42 ± 1.54 7.59 ± 1.65 <0.001 Urinary protein (g/day) 1.545 ± 2.128 0.818 ± 1.816 1.206 ± 2.057 1.640 ± 2.166 2.342 ± 2.096 <0.001 Urinary albumin (mg/gCr) 1064.4 ± 1512.3 538.7 ± 958.5 834.4 ± 1562.1 1176.4 ± 1446.3 1596.2 ± 1677.2 <0.001 Total chol (mg/dl) 194.3 ± 43.6 200.0 ± 37.1 197.2 ± 47.0 193.4 ± 41.0 187.1 ± 45.9 0.032 Non-HDL chol (mg/dl) 140.7 ± 42.1 141.8 ± 37.0 142.4 ± 44.8 140.7 ± 39.